13 completed. 13 Phase 1, 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 13 | Completed 13 |
| Phase 2 | 5 | Completed 5 |
Follow Systemic Sclerosis: new trials by email Literature Review of Systemic Sclerosis trials Research Report on Systemic Sclerosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of MK-2225 in Healthy Participants (MK-2225-003) MK-2225, Placebo - Systemic Sclerosis | Phase 1 | Completed | Merck Sharp & Dohme LLC | 32 | 2023-11-21 | 2025-07-29 |
| A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of RO7303509 in Participants With Systemic Sclerosis RO7303509, Placebo - Systemic Sclerosis | Phase 1 | Completed | Genentech, Inc. | 56 | 2023-01-16 | 2025-07-20 |
| A Study to Evaluate VIB7734 in Participants With Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus (CLE), Sjogren's Syndrome, Systemic Sclerosis, Polymyositis, and Dermatomyositis VIB7734, Placebo - Systemic Lupus Erythematosus, Cutaneous Lupus Erythematosus | Phase 1 | Completed | Amgen | 31 | 2018-12-13 | 2024-12-13 |
| A Study of KHK4827 in Patients With Systemic Sclerosis KHK4827 - Systemic Sclerosis | Phase 1 | Completed | Kyowa Kirin Co., Ltd. | 8 | 2017-10-06 | 2025-07-11 |
| Evaluation of Tofacitinib in Early Diffuse Cutaneous Systemic Sclerosis (dcSSc) Tofacitinib, Placebo Oral Tablet - Systemic Sclerosis, Scleroderma | Phase 1 / Phase 2 | Completed | University of Michigan | 15 | 2017-09-25 | 2020-05-08 |
| Prevalence and Predictors of Proton Pump Inhibitor Partial Response in Gastroesophageal Reflux Disease in Systemic Sclerosis Omeprazole 20mg - Systemic Sclerosis, Gastroesophageal Reflux | Phase 1 | Completed | Khon Kaen University | 250 | 2013-05-01 | 2018-06-21 |
| IL1-TRAP, Rilonacept, in Systemic Sclerosis Rilonacept, Placebo - Scleroderma, Systemic Sclerosis | Phase 1 / Phase 2 | Completed | Boston University | 24 | 2011-12-01 | 2018-05-01 |
| Pharmacokinetics of Oral Treprostinil in Patients With Systemic Sclerosis treprostinil diethanolamine - Systemic Sclerosis | Phase 1 | Completed | United Therapeutics | 28 | 2008-12-01 | 2012-10-23 |
| A Study Using The Experimental Drug Called Imatinib (Gleevec) in Subjects With Systemic Sclerosis Imatinib - Alveolitis, Systemic Sclerosis | Phase 1 / Phase 2 | Completed | University of California, Los Angeles | 20 | 2007-08-01 | 2014-10-27 |
| Rapamycin vs Methotrexate in Diffuse SSc rapamycin, methotrexate - Systemic Sclerosis | Phase 1 / Phase 2 | Completed | University of California, Los Angeles | 17 | 2002-08-01 | 2016-04-11 |
| Pilot Study of Total Body Irradiation in Combination With Cyclophosphamide, Anti-thymocyte Globulin, and Autologous CD34-Selected Peripheral Blood Stem Cell Transplantation in Children With Refractory Autoimmune Disorders Stem Cell Transplantation, CD34 selection - Systemic Sclerosis, Systemic Lupus Erythematosus | Phase 1 | Completed | Fred Hutchinson Cancer Center | 6 | 2000-11-01 | 2015-03-06 |
| Stem Cell Transplant to Treat Patients With Systemic Sclerosis Cyclophosphamide, Mesna, G-CSF - Systemic Sclerosis | Phase 1 | Completed | Baylor College of Medicine | 24 | 1999-06-01 | 2020-01-18 |
| Safety, Tolerability, and Pharmacokinetics of CAT-192 (Human Anti-TGF-Beta1 Monoclonal Antibody) in Patients With Early Stage Diffuse Systemic Sclerosis Human Anti-Transforming Growth Factor Beta-1 Monoclonal Antibody - Systemic Sclerosis, Scleroderma | Phase 1 / Phase 2 | Completed | Genzyme, a Sanofi Company | 2015-03-05 |
Scleroderma, Systemic (13) · Scleroderma, Diffuse (5) · Dermatomyositis (2) · Lupus Erythematosus, Systemic (2) · Arthritis (1) · Arthritis, Juvenile (1) · Autoimmune Diseases (1) · Communicable Diseases (1) · Connective Tissue Diseases (1) · Gastroesophageal Reflux (1) · Immune System Diseases (1) · Lupus Erythematosus, Cutaneous (1) · Polymyositis (1) · Rare Diseases (1) · Sjogren's Syndrome (1)
Skin Diseases (13) · Skin and Connective Tissue Diseases (13) · Connective Tissue Diseases (12) · Joint Diseases (2) · Muscular Diseases (2) · Musculoskeletal Diseases (2) · Myositis (2) · Nervous System Diseases (2) · Neuromuscular Diseases (2) · Rheumatic Diseases (2) · Arthritis (1) · Arthritis, Rheumatoid (1) · Autoimmune Diseases (1) · Deglutition Disorders (1) · Digestive System Diseases (1)
Cyclophosphamide (1) · Granulocyte Colony-Stimulating Factor (1) · Imatinib Mesylate (1) · Leukapheresis (1) · Mesna (1) · Methotrexate (1) · Omeprazole (1) · Sirolimus (1) · Stem Cell Transplantation (1) · Whole-Body Irradiation (1) · brodalumab (1) · rilonacept (1) · tofacitinib (1) · treprostinil (1)
University of California, Los Angeles (2) · Amgen (1) · Baylor College of Medicine (1) · Boston University (1) · Fred Hutchinson Cancer Center (1) · Genentech, Inc. (1) · Genzyme, a Sanofi Company (1) · Khon Kaen University (1) · Kyowa Kirin Co., Ltd. (1) · Merck Sharp & Dohme LLC (1) · United Therapeutics (1) · University of Michigan (1)
United States (11) · Poland (2) · Spain (2) · Argentina (1) · Belgium (1) · France (1) · Israel (1) · Japan (1) · Portugal (1) · Puerto Rico (1) · Serbia (1) · United Kingdom (1)
Ann Woolfrey (1) · Carol A. Wallace, MD (1) · Daniel E. Furst, MD (1) · Dinesh Khanna, MD (1) · Kristan Rollins, PharmD (1) · Philip J Clements, MD, MPH (1) · Robert W Simms, MD (1)
PMID 19950289, PMID 21769849, PMID 23597147, PMID 30277862, PMID 35943798, PMID 36997069
2018 (1)